SJURVM schreef op 29 mei 2017 13:22:
I will express my concerns with MDXH at the moment:
Slowdown in sales as per 4 month business update. Even though it was taken up by more urologists and covered by insurance companies.
Increase in number of personnel to "collect" the unrecognized revenue. Is this becoming a real problem?
Delay in launching Assuremdx (problem with the product or lack of cash? hence the deal with Exact?)
Suddenly the VA contract becomes extremely important. Why is that and what if it does not deliver?
No new insurance contracts signed in the USA because everyone is waiting for the introduction of 2018 CPT code? What happens in the last few months of 2017
Taglich Brothers used "publicly" available information to write their report in the past. Now they have "reliable sources". In their report the eps improves by $0.04 to -$0.20 by 2018. extrapolating this means it will take 5 years to break-even. Of course it is but one ratio. If there are new capital raising issue and or the sales go up even faster and or the costs go down it might be getting to break-even more quickly.
So, there you have it.
I am still looking forward to the €6.50 by year-end though :)